Few people who take a serious interest in medicine or the state of the nation's health have anything but praise for the scientific achievements of the pharmaceutical industry and the contribution its research and new products have made to the 'health revolution' of recent decades. The criticisms that are made concerning the industry relate for the most part to economic matters: the industry being attacked for charging too high prices and with making exorbitant profits; with spending excessive sums of money on advertising and sales promotion; and with generally not giving value for money to the British taxpayer who finances the National Health Service. It is with these economic matters that my contribution to this symposium is concerned.
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Characteristics of the Pharmaceutical Industry
The pharmaceutical industry is among the fastest growing sectors of British manufacturing industry. Over the eight years 1955-63 growth was, in terms of assets, over 200% (£33-8 million to £106-8 million). In 1958 ex-industry sales were £138 million, by 1965 they had risen by 82% to £251 milliona 9% annual average growth rate. This may be compared with the 3-5 % growth rate achieved by manufacturing industry as a whole in this period and the 6 % achieved by the chemical industry. The pharmaceutical industry is a growth sector of a growth industry and it will be appreciated that the achievement of such a high growth rate requires both an incentive in the sense of prospects of profit and high profit itself to provide the funds for the capital expansion.
The industry has not only contributed its full share to domestic economic growth but has also been a successful exporter. In recent years, over 25% of the industry's net sales have been to overseas customers which compares very favourably with the 16% of manufacturing industry in general. These exports have been concentrated in some of the most advanced and competitive markets of the world, for example the EEC and EFTA countries.
The pharmaceutical industry is exceptional in that it is almost entirely composed of subsidiary companies, a high proportion of which are owned by foreign parents. British-owned firms supply only about 25 % of domestic demand; USA subsidiaries about 55 %; and the rest is from Swiss (13 %), French, German and Dutch companies. Of the ten leading firms, based on 1965 sales to the NHS, all but two (Beechams and Glaxo) were foreign owned and controlled and it is, perhaps, worth making the point that the growth and the export successes referred to in the previous paragraphs are in part a reflection of the activities of these foreign-owned companies; in 1963, for example, no less than half the exports of chemical pharmaceuticals were made by subsidiaries of companies owned outside the UK. It should equally be recognized that the contribution of British firms on the export front has been particularly important; on the whole they have exported a significantly higher proportion of their output than foreign-owned subsidiaries.
The success of most of the important firms in the industry depends upon the research effort of the laboratories and the extent to which this leads to marketable new drugs. A major reason for this is, of course, the high regard which people attach to their health and their desire (and their doctor's desire) that they should receive the most effective treatment for any illness from which they may suffer. In the case of the UKand also a number of other countriesthis desire is probably enhanced by administrative arrangements which break any direct relationship between the cost of treatment and the amount charged to the patient. Under the NHS, for example, the doctor is free to prescribe what he wishes and the cost of the particular drug selected does not fall directly on the patientor, of course, the doctor. Price does not, therefore, play its economic role as a major influence on the level and pattern of consumption. It follows that competition through price cutting is likely to be abortive, and must thereforeif it is to exist at alltake other forms; and the form it takes is of research and development on the one hand and of sales promotion efforts on the other.
Research is so active and so successful in the industry that some 50% of the leading products available in 1965 were unheard of in 1960. Competition in research is effective. Firms in the industry are often accused of being in a monopolistic position with respect to a particular product and henceso it is often suggestedare in a position to make substantial profits. At any one moment of time this may well be the case. But it usually happens that in a fairly short space of time this position is challenged by a successful research and development effort elsewherepatents and brand names notwithstanding.
Research does, of course, cost a lot of money and it has been estimated that some £11 6 million was spent by the industry on research in 1965. These funds are heavily concentrated. About £3 million is spent by the (few) overseas firms doing research in this country. Of the rest, well over half is spent by five British-owned companies: these firms spend about one-third of their total sales income on research.
A point which is important for my future argument is how small these UK research budgets are when looked at in an international context; it seems, for example, that firms spend some £140 million in the USA, and £20 million in Switzerland. As what evidence we have suggests that, taking one year with another, research expenditure pays off in the form of new products, it would seem that unless the UK is to contract out of the industrywith adverse consequential effects on the balance of payments and the economy generallyit is vital to maintain and if possible increase the research expenditure of British-owned and British-located firms.
Given the importance of product rather than price competition, it is not surprising that pharmaceutical firms have spent heavily in advertising and promoting their products to the doctors who prescribe them. No one would deny that excessive expenditure may sometimes be made in this way or that exaggerated claims for a particular new product may from time to time be expressed. Equally, however, there can be little doubt that the availability of new drugs is brought to the attention of doctors with great rapidity and that on the whole this is to the benefit of patients.
Profitability
At least since the discussions before the 1959-60 Public Accounts Committee there has been a tendency for many honest and reasonable people to think that firms in the pharmaceutical industry make unduly high profits. More recently the Sainsbury Committee felt able to conclude that excessive profits to the extent of several million pounds over a three-year period had been earned at the expense of the NHS. In my judgment, the view of the Sainsbury Committee on profitability was crucial in bringing it to many, if not most, of its recommendationsparticularly those relating to pricing and sales promotion. For reasons given in outline below, I do not consider the Committee's arguments on profitability to be very convincing; it follows in my view that its economic recommendations are not well founded.
Neither in the Report nor in the Financial Appendix does the Sainsbury Committee compare the profitability of the pharmaceutical industry with other industries or the profitability of firms in the pharmaceutical industry with firms in other industries. Instead, the profitability of firms in the pharmaceutical industry is put alongside the profitability of industry as a whole. Moreover, no attempt at all is made to take account of any of the special features of the industry, such as rapid growth and the need for risky research investment, in considering what is and what is not an appropriate rate of profit. This might have been donein part at leastby putting statistics relating to the pharmaceutical industry alongside those relating not to industry as a whole but to industries possessing at least some of the economic characteristics of the pharmaceutical industry.
Work done in my department, some published, some unpublished (e.g. Cooper 1966 , Cooper & Parker 1967 , 1968 , suggests that it would be very unwise to accept at their face value profitability calculations as normally presented which on the whole do seem to show a high level of profitability. One aspect of this work emphasizes the statistical problems which arise due to the subsidiary nature of the industry, for such companies are able to call upon their parent company for many services, the cost of which may not be fully reflected in the subsidiary's accounts. Work covering the accounts of 411 foreign subsidiaries 1207 in all industries for the period 1959 -66 (Cooper & Parker 1967 suggests that the normal method of measuring profitability (gross profit as a percentage of total net capital assets) tends to overstate the profits of subsidiariestheir average rate of return worked out at some 23 % in 1965 compared with a figure for (quoted) industry as a whole of 14%. If one does the calculation on a rather different basis, i.e. gross profit with respect to total assets, which in our view makes the comparison more appropriate from the point of view of a subsidiary company, then the ratios become 14% and 12% respectivelya much smaller gap. We found also that American subsidiaries tended to have a slightly higher rate of profitabilityon both measuresas compared with subsidiaries as a whole.
It has already been shown how the pharmaceutical industry is heavily dominated by foreign, particularly American, subsidiary companies. It follows that the point made about measuring profitability in subsidiaries applies with special force to attempts to compare relative profitability in pharmaceutical and other industries. The usual approachwhich suggests that the pharmaceutical industry has a profit rate substantially above industry as a wholeis not of much value here and a total asset approach is needed. (It is, of course, appreciated that this meets only one of the problems arising from the subsidiary structure of the industry.) On a net asset basis the average profitability of the industry from 1954 to 1963 is 305 % compared with an overall figure of about 16%. (The industry's profit rate declined through this period, being 38-8 % in 1954 and 27-9 % in 1963.) On a total asset basis average profitability was 201 % (22-7 % in 1954, 16-4 % in 1963) compared with a national average of about 12%. Doing the calculations in a way more appropriate to an industry dominated by subsidiaries reduces the 'excess' profitability substantially. If one goes further and compares the profitability of individual sections of the pharmaceutical industry -UK quoted companies, American subsidiary companies, &c. -with the relevant national statistics the excess profitability is further reduced. It is still further reduced if one compares the pharmaceutical industry with an (appropriate) sector of another industry having some of the same basic characteristics.
The main point is that the simple calculations which have so often been used to suggest that profits in the industry are very high cannot be accepted as demonstrating this. Given the need for growth and the requirements of research, the evidence in no way suggests that the rate of return in the industry as a whole is excessive; on the contrary, the rate obtained may well be less than is needed for efficient growth.
Policy
Finally, the problems and opportunities of the firms located in the UK need to be considered more in the context of the development of the economy as a whole than in the context of obtaining value for money in the NHSthough as just indicated the existence of excessive profits has not been proved.
If the UK economy is to achieve a respectable rate of growth there is general agreement that research and science based industries like chemicals and electronics must contribute substantially to the required growth of exports. As the developing countries produce the simpler manufactures, so countries like the UK must produce and sell the more complicated goodsif they are to export at all. What is true generally applies also to pharmaceuticals. With the development of local production of simple drugs, success in international trade depends on exporting the latest and more sophisticated products. Moreover, the high costs of research make it necessary for firms to look outside their domestic markets if they are to recoup this expenditure. Success in trade will depend in large part on the success or otherwise of the firm's (or country's) research and development laboratories. Thus the circle is complete. On the one hand research needs the financial backing likely to be available only in firms selling to the world market and whose domestic prices are not depressed too severely; on the other hand, an international market will be won only by firms with large research budgets producing a stream of innovations.
Given the size of the UK firms' research budgets already mentioned, there are clearly problems. Yet there are grounds for hope. British firms have shown that they can innovate and a number of foreign subsidiaries have established research as well as production divisions. The crucial issue of policy today with respect to the industry is how to achieve over a period of years an increase in exports and in the flow of marketable innovationswith, of course, due regard for the interests of the Department of Health and Social Security. Policy should be directed towards encouraging the growth of the industry in the interests of the economy as a whole; emphasis should not be just on how to obtain drugs for the NHS at the lowest possible costas so often has seemed to be the case in the past.
